Immuno-Oncology

Marc Ernstoff, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses results from a study examining the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced BRAF-mutated or BRAF wild-type melanoma.

The European Commission has approved nivolumab as a treatment for patients with advanced melanoma in the first- and later-line setting regardless of BRAF mutation status, making it the first PD-1 inhibitor to gain approval in Europe.

For clinicians, a central message from 2015 ASCO is that a framework for managing immune-related adverse events in patients who receive these immune checkpoint agents is taking shape.

Nivolumab continued to show high activity and a good safety profile after more than a year of follow-up in heavily pretreated patients with relapsed or refractory lymphoid malignancies or those with classical Hodgkin lymphoma.

Laurie H. Glimcher, MD, discusses the promise of XBP1 inhibition as an immunotherapy strategy in ovarian cancer.

The ASCO annual meeting has retained its core purpose of providing a unique platform for oncologists to interact and exchange the latest practice-changing research.

Julie R. Brahmer, MD, interim director, Sidney Kimmel Comprehensive Cancer Center, associate professor of oncology, Johns Hopkins Medicine, discusses how the CheckMate-057 trial could impact the treatment of non-small cell lung cancer (NSCLC).

Jedd D. Wolchok, MD, discusses the unique design and goals of the CheckMate-067 trial, and what its results mean for patients with advanced melanoma going forward.